Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 18 Aug 2017 |
| Orion Corporation: Managers’ transactions – Heikki Westerlund | 17 Aug 2017 |
| 146,000 Orion Corporation A shares converted into B shares | 1 Aug 2017 |
| Orion Group Half-Year Financial Report January-June 2017 | 19 Jul 2017 |
| Orion Corporation's financial reporting and Annual General Meeting in 2018 | 19 Jul 2017 |